Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.84 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL14472019 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL5598406 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2225672 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3013 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL25969 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3014 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL27522597 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6317379 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2817795 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2175991 | 0.97 | HMGCR (0.98) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708434-B2 | Multigraft copolymers as superelastomers | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2622015-B1 | MULTIGRAFT COPOLYMERS AS SUPERELASTOMERS | UNIV TENNESSEE RES FOUNDATION (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20140161858-A1 | Multigraft Copolymers as Superelastomers | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2622015-A1 | MULTIGRAFT COPOLYMERS AS SUPERELASTOMERS | University of Tennessee Research Foundation (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012106584-A2 | PITAVASTATIN SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012045006-A1 | MULTIGRAFT COPOLYMERS AS SUPERELASTOMERS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-04-05 | — | — | WO | disclosed |
| CN-101580466-B | Preparation method of sodium salt of naftifidine | SHANGHAI TECHWELL BIOPHARM CO | 2012-04-04 | — | — | CN | disclosed |
| CN-101580466-A | Preparation method of sodium salt of pravastatin | SHANGHAI TECHWELL BIOPHARMACEU (CN) | 2009-11-18 | — | — | CN | disclosed |
| US-20070185193-A1 | Huvastatin and its preparation and formulation comprising the huvastatin | HUAIBEI HUIKE PHARMACEUTICAL, CO. LTD. (CN) | 2007-08-09 | — | — | US | disclosed |
| EP-1693360-A1 | HUVASTATIN AND ITS PREPARATION AND FORMULATION COMPRISING THE HUVASTATIN | HUAIBEI HUIKE PHARMACEUTICAL CO., LTD. (CN) | 2006-08-23 | — | — | EP | disclosed |
| US-6833004-B2 | Stent | TERUMO KABUSHIKI KAISHA (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030033004-A1 | Stent | TERUMO KABUSHIKI KAISHA (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1273314-A1 | Stent | TERUMO KABUSHIKI KAISHA (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185193-A1 | Huvastatin and its preparation and formulation comprising the huvastatin | PCSK9, HMGCR, LDLR | HMGCR 2/4885ALOX15 1397/4885SLCO1B1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.